Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. More Details
Earnings have declined by 52.5% per year over past 5 years
Makes less than USD$1m in revenue (SEK-22M)
Has less than 1 year of cash runway
Significant insider selling over the past 3 months
+ 1 more risk
Excellent balance sheet with weak fundamentals.
Search for a company to compare.